-- Livzon Pharmaceutical Group's (SHE:000513, HKG:1513) obtained approval to conduct a clinical trial of JP-1366 Tablet from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.
The approval is for the indication of the combination of the drug with appropriate antibiotics for the eradication of Helicobacter pylori.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:HCA Healthcare delivered Q1 2026 EPS of $7.15, in line with consensus and up 10.9% Y/Y, while revenue of $19.109B grew 4.3% and beat the $19.07B consensus estimate. Same-facility admissions rose 1.3%, though surgical volumes declined with inpatient and outpatient surgeries down 0.3% and 1.7%, respectively, reflecting softness in elective procedures and seasonal headwinds. Strong share repurchase activity of $1.571B during the quarter supported EPS growth despite volume pressures. Management reaffirmed 2026 guidance ranges, indicating confidence in navigating policy headwinds. Adjusted EBITDA margin compressed 50 bps to 19.9% due to challenging volumes and inflationary cost pressures, though operating cash flow surged 22% to $2.014B. We view the continued strong cash generation and $9.179B remaining share repurchase authorization as supportive of capital returns despite headwinds from ACA enhanced premium tax credit expirations and OBBBA Medicaid funding cuts.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to $100 from $75, on a P/E of 33.3x our 2028 EPS, above peers/historical to reflect our view of upside to margins/estimates. After the better than expected Q1/Q2 guide, we lift our 2026 EPS to $1.05 from $0.70, 2027 to $1.40 from $1.30, and 2028 to $3.00 from $2.64. We expect INTC's revenue trajectory to benefit from greater content share in AI servers, where the CPU-to-accelerator ratio is moving from 1:8 back toward 1:4 or potentially parity, driven by inference, agentic AI, and physical AI workloads that are more CPU-intensive. This positions the Xeon franchise for strong, sustainable demand, with a product pipeline that is ramping the fastest in five years. Within the client segment, AI PCs are now over 60% of the client CPU mix. We are also encouraged by Intel Foundry momentum amid leading-edge wafer capacity shortages, with the Elon Musk Terafab partnership and multi-year long-term agreements with Google providing major endorsements. Intel 18A process yields are tracking well.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price to $96 from $79, 7.8x our 2027 EPS view vs. BFH's three-year historical forward P/E average of 6.2x and the peer average of 7.1x. We increase our 2026 EPS estimate to $11.30 from $9.70 and 2027's to $12.30 from $11.62, reflecting the company's significant Q1 earnings beat and the substantial impact of an accelerated share repurchase program. A key win from Q1 was the company's return to loan growth, reversing prior-period declines with a 2% Y/Y increase in end-of-period loans. This inflection was underpinned by robust consumer activity, with credit sales accelerating to 7% growth. Furthermore, credit metrics continued their gradual improvement, with the delinquency rate falling to 5.6% and the net loss rate decreasing to 7.3%. Management prudently maintained its 2026 outlook for low single-digit growth in both average loans and revenue, with net loss rate guidance of 7.2%-7.4%, a move we believe wisely accounts for ongoing macroeconomic uncertainty and geopolitical tensions.